Age an Important Factor in RA Disease Progression

Published Online: Thursday, February 14, 2013
Follow Pharmacy_Times:
According to a study published online on January 9, 2013, by Clinical and Experimental Rheumatology, disease progression in rheumatoid arthritis (RA) patients is more affected by disease duration than age of onset.

Researchers of the study compared the symptoms and treatment of patients with young-onset RA with those of patients with lateonset RA from the national database of the German Collaborative Arthritis Centres from 2007 to 2009. The researchers identified 9541 patients and split them into 2 groups: patients who were 65 years and younger at diagnosis (young onset) and patients who were older than 65 years at diagnosis (late onset). The researchers performed 2 separate matched-pair tests to analyze the impact of current age and the impact of age at diagnosis.

At the same age, patients diagnosed at 65 years and younger had higher disease activity, less functional ability, and were less frequently in remission when compared with patients who were diagnosed when older than 65 years. Young-onset patients also had higher rates of RA-related comorbidities, including cardiovascular disease, chronic renal disease, and osteoporosis.

In addition, lateonset patients took disease-modifying antirheumatic drugs (DMARDs) at lower rates than their young-onset counterparts. Even though this population was in remission more frequently, the researchers suggest that a deficit in treatment may exist for older patients with respect to DMARDs.

Related Articles
Lilly and Incyte have recently announced positive results from the second phase 3 study of their investigational drug baricitinib, a potential treatment for rheumatoid arthritis.
Patients with celiac disease are known to be deficient in the amino acid L-carnitine, a nutrient essential for muscle energy production.
Amgen has announced positive results of a phase 3 study evaluating its investigational drug, ABP 501, a biosimilar candidate to AbbVie’s fully human anti-tumor necrosis factor alpha monoclonal antibody, adalimumab, in patients with moderate-to-severe rheumatoid arthritis.
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times